12 citations
,
September 2002 in “Epilepsia” This paper discusses the methods and challenges of postmarketing surveillance for new antiepileptic drugs, emphasizing the necessity of such data collection to identify adverse effects and assess drug effectiveness beyond initial trials.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.
12 citations
,
January 2007 in “Acta dermato-venereologica” This review discusses the classification and regulation challenges of anti-ageing cosmetics in Europe and reports no new findings; it calls for increased transparency to help consumers make informed choices.
April 2018 in “Expert Opinion on Drug Safety” The authors concluded that finasteride should be preferred over dutasteride for treating male androgenetic alopecia, as it better preserves certain important functions.
September 2025 in “The Journal of Clinical Psychiatry” Current evidence reviewed in this study indicates that finasteride, a drug for hair loss, can cause depression and suicidality, with delayed recognition partly due to insufficient post-approval pharmacovigilance by manufacturers and regulators.